Eric M Dube Travere Therapeutics, Inc. (TVTX) insider trading activity

Eric M Dube is CHIEF EXECUTIVE OFFICER of Travere Therapeutics, Inc.. Currently has a direct ownership of 361,975 shares of TVTX, which is worth approximately $6.22 Million. The most recent transaction as insider was on Sep 09, 2024, when has been sold 21,125 shares (Common Stock) at a price of $11.52 per share, resulting in proceeds of $243,360. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 362K

0% 3M change

49.21% 12M change

Total Value Held $6.22 Million

Eric M Dube Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 09 2024	SELL Open market or private sale	$243,360 $11.52 p/Share	21,125 Reduced 5.51%	361,975 Common Stock
Sep 05 2024	BUY Grant, award, or other acquisition	-	32,500 Added 7.82%	383,100 Common Stock
Feb 01 2024	SELL Open market or private sale	$166,361 $8.7 p/Share	19,122 Reduced 5.17%	350,600 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	135,000 Added 26.75%	369,722 Common Stock
Jan 23 2024	SELL Open market or private sale	$70,542 $8.96 p/Share	7,873 Reduced 3.25%	234,722 Common Stock
Sep 05 2023	SELL Open market or private sale	$65,533 $14.71 p/Share	4,455 Reduced 1.8%	242,595 Common Stock
Aug 31 2023	BUY Grant, award, or other acquisition	-	9,900 Added 3.85%	247,050 Common Stock
Feb 01 2023	SELL Open market or private sale	$182,361 $22.25 p/Share	8,196 Reduced 3.34%	237,150 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	97,500 Added 28.44%	245,346 Common Stock
Jan 24 2023	SELL Open market or private sale	$138,503 $21.5 p/Share	6,442 Reduced 4.18%	147,846 Common Stock
Jan 05 2023	SELL Open market or private sale	$116,718 $20.75 p/Share	5,625 Reduced 3.52%	154,288 Common Stock
Feb 10 2022	SELL Open market or private sale	$134,523 $27.84 p/Share	4,832 Reduced 2.93%	159,913 Common Stock
Jan 31 2022	SELL Open market or private sale	$131,876 $27.4 p/Share	4,813 Reduced 2.84%	164,745 Common Stock
Jan 31 2022	BUY Grant, award, or other acquisition	-	37,848 Added 18.25%	169,558 Common Stock
Jan 24 2022	SELL Open market or private sale	$196,668 $24.98 p/Share	7,873 Reduced 5.64%	131,710 Common Stock
Jan 05 2022	SELL Open market or private sale	$377,000 $30.16 p/Share	12,500 Reduced 8.22%	139,583 Common Stock
Jan 04 2022	SELL Open market or private sale	$147,038 $30.43 p/Share	4,832 Reduced 3.08%	152,083 Common Stock
Aug 17 2021	SELL Open market or private sale	$134,152 $17.12 p/Share	7,836 Reduced 4.76%	156,915 Common Stock
Aug 13 2021	BUY Grant, award, or other acquisition	-	17,500 Added 9.6%	164,751 Common Stock
Jun 02 2021	SELL Open market or private sale	$68,593 $14.35 p/Share	4,780 Reduced 3.14%	147,251 Common Stock
Jun 01 2021	SELL Open market or private sale	$71,204 $14.89 p/Share	4,782 Reduced 3.05%	152,031 Common Stock
Feb 08 2021	SELL Open market or private sale	$151,995 $31.58 p/Share	4,813 Reduced 2.98%	156,813 Common Stock
Feb 05 2021	SELL Open market or private sale	$151,176 $31.41 p/Share	4,813 Reduced 2.89%	161,626 Common Stock
Feb 03 2021	SELL Open market or private sale	$69,557 $28.91 p/Share	2,406 Reduced 1.59%	148,939 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	17,500 Added 9.51%	166,439 Common Stock

Also insider at

RPHM

Reneo Pharmaceuticals, Inc. Healthcare

Director

EMD

Eric M Dube

CHIEF EXECUTIVE OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Value

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX

Account